| Literature DB >> 34946308 |
Antonio Currà1, Lucio Marinelli2,3, Filippo Cotellessa3,4, Laura Mori3,4, Chiara Avanti3,4, Daniela Greco1, Manuela Gorini1, Paolo Missori5, Francesco Fattapposta6, Carlo Trompetto3,4.
Abstract
Background andEntities:
Keywords: cognitive impairment; dementia; habituation; neurophysiology; somatosensory evoked potentials
Mesh:
Year: 2021 PMID: 34946308 PMCID: PMC8708528 DOI: 10.3390/medicina57121364
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Patients’ demographic data and score on cognitive screening.
| Patient | Grp | Age | Sex | Education (Years) | MMSE | Memory Enhancing Drugs |
|---|---|---|---|---|---|---|
| 1 | AD-type | 76 | F | 5 | 18 | Donepezil 10 mg Memantine 20 mg |
| 2 | AD-type | 79 | M | 13 | 22 | None |
| 3 | AD-type | 62 | M | 5 | 20 | Galantamine 16 mg |
| 4 | AD-type | 75 | F | 8 | 22 | Rivastigmine 9 mg |
| 5 | AD-type | 68 | F | 13 | 21 | None |
| 6 | AD-type | 78 | F | 0 | 20 | Galantamine 16 mg |
| 7 | AD-type | 78 | F | 3 | 22 | Donepezil 5 mg |
| 8 | AD-type | 80 | M | 16 | 21 | Memantine 20 mg |
| 9 | AD-type | 65 | F | 5 | 19 | None |
| 10 | AD-type | 68 | F | 13 | 22 | Rivastigmine patch 4.5 mg |
| 11 | AD-type | 79 | F | 5 | 20 | Donepezil 5 mg |
| 12 | AD-type | 82 | F | 5 | 18 | None |
| 13 | AD-type | 74 | F | 5 | 21 | Galantamine 16 mg |
| 14 | AD-type | 77 | F | 5 | 18 | Rivastigmine patch 13.3 mg |
| 15 | AD-type | 80 | F | 9 | 20 | Galantamine 16 mg |
| 16 | VD-type | 86 | F | 5 | 18 | |
| 17 | VD-type | 70 | F | 5 | 21 | |
| 18 | VD-type | 74 | M | 5 | 19 | |
| 19 | VD-type | 75 | M | 5 | 22 | |
| 20 | VD-type | 82 | M | 5 | 22 | |
| 21 | VD-type | 84 | F | 5 | 18 | |
| 22 | VD-type | 85 | M | 5 | 20 | |
| 23 | VD-type | 83 | F | 17 | 22 | |
| 24 | VD-type | 73 | M | 8 | 19 | |
| 25 | VD-type | 80 | F | 3 | 21 | |
| 26 | VD-type | 69 | F | 5 | 19 | |
| 27 | VD-type | 80 | F | 4 | 18 | |
| 28 | VD-type | 89 | F | 5 | 18 | |
| 29 | VD-type | 77 | M | 5 | 22 |
Neuropsychological tests’ scores in AD-type patients.
| ORIENTATION | MEMORY | ACE-R | FLUENCIES | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | MMSE | Temporal | Spatial | Personal | Raven | Digit for | Digit back | Rey Immediate | Rey Delayed | Prose Immediate | Prose Delayed | Oblivion | Orientation | Memory | Fluency | Language | Visuo-Spatial | Tot. | Phonemic | Semantic |
| 1 | 18 | 74 | +/- | - | 13 | 8 | 7 | 23 | 9 | 60 | ||||||||||
| 2 | 22 | 96 | + | + | 4 | 3 | 20 | 0 | 1 | 0 | 1 | 25 | 10 | |||||||
| 3 | 20 | 94 | + | - | 3.3 | 2 | 1.3 | 13 | 7 | 5 | 16 | 6 | 47 | 15 | 9 | |||||
| 4 | 22 | 94 | + | + | 24 | 4 | 2 | 3.3 | 0 | 3.3 | 13 | 15 | 6 | 21 | 12 | 67 | 15 | 11 | ||
| 5 | 21 | 90 | + | +/- | 18 | 1 | 27 | 7 | ||||||||||||
| 6 | 20 | 87 | + | - | 12 | 9 | 9 | 21 | 10 | 61 | ||||||||||
| 7 | 22 | 98 | + | + | 21 | 3 | 2 | 22 | 2 | 5.3 | 2.3 | 3 | 16 | 16 | 6 | 23 | 13 | 74 | 18 | 9 |
| 8 | 21 | 88 | + | + | 28 | 4.6 | 1 | 3.6 | 14 | 18 | 9 | 25 | 14 | 76 | 23 | 12 | ||||
| 9 | 19 | 83 | - | +/- | 14 | 4 | 0 | 4 | 9 | 8 | 6 | 17 | 4 | 44 | 11 | 9 | ||||
| 10 | 22 | 100 | + | + | 30 | 5 | 4 | 32 | 3 | 5 | 2.2 | 2.8 | 17 | 11 | 9 | 26 | 15 | 78 | 39 | 11 |
| 11 | 20 | 90 | +/- | - | 18 | 3 | 5 | 3 | 2 | 1 | 8 | |||||||||
| 12 | 18 | 82 | - | - | 11 | 11 | 8 | 21 | 11 | 62 | ||||||||||
| 13 | 21 | 90 | +/- | +/- | 12 | 13 | 6 | 21 | 9 | 61 | 17 | 9 | ||||||||
| 14 | 18 | 92 | +/- | +/- | 13 | 10 | 7 | 20 | 11 | 61 | ||||||||||
| 15 | 20 | 76 | + | + | 18 | 11 | 7 | 8 | 17 | 10 | 53 | 24 | 11 | |||||||
| 16 | 18 | 77 | - | - | 10 | 8 | 6 | 21 | 13 | 58 | ||||||||||
Neuropsychological tests’ scores in VD-type patients.
| ORIENTATION | MEMORY | ACE-R | FLUENCIES | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | MMSE | Temporal | Spatial | Personal | Raven | Digit for | Digit back | Rey Immediate | Rey Delayed | Prose Immediate | Prose Delayed | Oblivion | Orientation | Memory | Fluency | Language | Visuo-Spatial | Tot. | Phonemic | Semantic |
| 17 | 21 | 91 | + | - | 16 | 4 | 2 | 9 | 1 | 0 | 0 | 0 | 7 | 8 | ||||||
| 18 | 19 | 89 | + | +/- | 12 | 11 | 8 | 22 | 13 | 66 | ||||||||||
| 19 | 22 | 94 | + | + | 14 | 4 | 0 | 4 | 15 | 11 | 6 | 20 | 9 | 61 | 18 | 10 | ||||
| 20 | 22 | 100 | + | + | 20 | 5 | 3 | 3.1 | 3 | 1.1 | 16 | 13 | 7 | 24 | 14 | 72 | 18 | 9 | ||
| 21 | 18 | 88 | + | +/- | 5 | 4 | 17 | 0 | 3 | 0 | 3 | 25 | 13 | |||||||
| 22 | 20 | 100 | + | + | 17 | 3 | 0 | 3 | 15 | 8 | 8 | 20 | 9 | 60 | 22 | 12 | ||||
| 23 | 22 | 100 | + | + | 27 | 5 | 3 | 18 | 0 | 2.2 | 2 | 0 | 18 | 11 | 8 | 25 | 14 | 76 | 10 | 12 |
| 24 | 19 | 86 | + | +/- | 3 | 2 | 19 | 3 | 2 | 2 | 0 | 9 | 5 | |||||||
| 25 | 21 | 91 | +/- | + | 13 | 14 | 5 | 20 | 11 | 63 | 12 | 10 | ||||||||
| 26 | 19 | 76 | + | - | 13 | 10 | 7 | 22 | 10 | 62 | ||||||||||
| 27 | 18 | 78 | +/- | +/- | 12 | 10 | 6 | 18 | 12 | 58 | ||||||||||
| 28 | 18 | 75 | - | - | 12 | 8 | 7 | 22 | 14 | 63 | ||||||||||
| 29 | 22 | 90 | + | + | 29 | 3 | 0 | 3 | 13 | 10 | 6 | 20 | 13 | 62 | 10 | 13 | ||||
Figure 1SEPs habituation from block 1 to block 3 in a representative patient with VD-type cognitive disorder. Top row grand average of trials 1-200 (block 1), mid row grand average of trials 201-400 (block 2), bottom row grand average of trials 401-600 (block 3).
Figure 2Lack of SEPs habituation from block 1 to block 3 in a representative patient with AD-type cognitive disorder. Top row grand average of trials 1-200 (block 1), mid row grand average of trials 201-400 (block 2), bottom row grand average of trials 401-600 (block 3).
Figure 3N20-P25 amplitude decreased from block 1 to block 3 in AD-type, VD-type cognitive disorder patients and healthy controls. N20-P25 amplitude remained unchanged from block 1 to block 3 in patients with AD-type cognitive disorder.